Systolic Hypertension in Europe (Syst-Eur) Trial Phase 2 : objectives, protocol, and initial progress

The Systolic Hypertension in Europe (Syst-Eur) trial proved that blood pressure (BP) lowering therapy starting with nitrendipine reduces the risk of cardiovascular complications in older (⩾60 years) patients with isolated systolic hypertension (systolic BP ⩾160 mm Hg and diastolic BP

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of human hypertension 1999-02, Vol.13 (2), p.135-145
Hauptverfasser:	GASOWSKI, J, STAESSEN, J. A, DOLLERY, C. T, DUGGAN, J, KAWECKA-JASZCZ, K, LEONETTI, G, NACHEV, C, SAFAR, M, RODICO, J. L, ROSENFELD, J, SEUX, M. L, TUOMILEHTO, J, CELIS, H, WEBSTER, J, YODFAT, Y, FAGARD, R. H, THIJS, L, BIRKENHÄGER, W. H, BULPITT, C. J, FLETCHER, A. E, ARABIDZE, G. G, DE LEEUW, P
Format:	Artikel
Sprache:	eng
Schlagworte:	Analgesics Antihypertensives Biological and medical sciences Blood pressure Cardiovascular diseases Dihydropyridine Hydrochlorothiazide Hypertension Medical sciences Neuropharmacology Patients Pharmacology. Drug treatments Placebos
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The Systolic Hypertension in Europe (Syst-Eur) trial proved that blood pressure (BP) lowering therapy starting with nitrendipine reduces the risk of cardiovascular complications in older (⩾60 years) patients with isolated systolic hypertension (systolic BP ⩾160 mm Hg and diastolic BP
ISSN:	0950-9240 1476-5527
DOI:	10.1038/sj.jhh.1000769